Desk note · industry · Healthcare / drug pricing
New ceiling prices for 543 cancer medicine brands take effect on 9 November
On 28 October 2026 the National Pharmaceutical Pricing Authority published revised maximum retail prices for 543 brands of anti-cancer medicines, effective 9 November 2026, reflecting company submissions under margin rules and including steep cuts on several molecules such as anastrozole tablets whose listed pack price fell from about ₹696 to ₹73 in one example cited in the release.

- •NPPA released a revised MRP list for 543 anti-cancer medicine brands on 28 October 2026, effective 9 November 2026.
- •The list reflects prices submitted by manufacturers for non-scheduled oncology drugs under trade-margin rules.
- •Examples in the release include sharp reductions, such as anastrozole 1 mg tablets falling from ₹695.76 to ₹73 for a ten-tablet pack under one brand.
What's going on here?
On 28 October 2026 the National Pharmaceutical Pricing Authority, under the Ministry of Chemicals and Fertilisers, published a table of revised maximum retail prices for 543 brands of anti-cancer medicines. The new prices take effect on 9 November 2026. The authority said the list captures information submitted by companies up to that Tuesday and will be updated as manufacturers file further revisions for non-scheduled oncology products. The release includes illustrative cuts, such as anastrozole 1 mg tablets marketed as Anarzole by RPG Life Sciences, where the listed pack price drops from ₹695.76 for ten tablets to ₹73. Similar rows cover injections and other formulations from large Indian and multinational suppliers.
What does this mean?
Earlier in October, policymakers moved to cap trade margins on many non-scheduled cancer drugs at 30%, targeting the mark-up between wholesaler and patient rather than factory gate prices alone. Publishing brand-level MRPs turns that policy into checkout prices at pharmacies and hospital desks. Patients on long-term oncology regimens may see immediate savings on listed brands, while hospitals that earned spread on in-house pharmacies could face tighter economics. Manufacturers must align billing systems and stock labels before 9 November; pharmacies need to avoid charging older sticker prices on affected packs.
Why should I care?
If you or a family member uses branded cancer medicines, ask your oncologist and pharmacist whether your prescription appears on the 9 November list and whether a therapeutically equivalent brand is available at the revised price. Carry prior bills if you dispute overcharges during the transition week. If you invest in hospital or pharma distributors, treat the list as operational detail following the margin-cap announcement, not a one-day sentiment trade. Watch NPPA updates for additional brands, state drug controller enforcement, and whether insurers adjust copay rules on outpatient oncology purchases.
More desk notes
Markets / GIFT IFSC
GIFT Nifty open interest set a fresh record above $22 billion
NSE International Exchange said on 19 November 2026 that GIFT Nifty open interest reached $22.21 billion on 18 November, topping the prior October peak as offshore index contracts keep drawing hedging and speculative flow at GIFT City.
Financial services / broking
Fairfax now owns more than half of IIFL Capital Services
FIH Mauritius Investments bought an 11.8% block from promoters on 19 November 2026 for about ₹1,540 crore, lifting the Fairfax group's combined holding in IIFL Capital Services Ltd past 50% as it funds the IDBI Bank takeover.
Power transmission
Adani Energy won a Bihar link for a 2,400 megawatt power plant
Adani Energy Solutions Ltd secured a tariff-based transmission project on 19 November 2026 to evacuate power from the 2,400 MW Pirpainti thermal plant in Bihar, adding 881 circuit kilometres and about ₹500 crore of annual regulated revenue when the lines go live by late 2028.
Consumer durables / travel goods
VIP Industries is pushing premium luggage after two growth quarters
Managing director Atul Jain said on 19 November 2026 that VIP Industries grew consolidated revenue 15% in the September quarter, narrowed losses, and leaned on premium SKUs, roughly 65 new ranges, and wider retail reach while passing three price hikes totalling 7–8% in six months.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.